Overview
Improving Outcomes for an Aging Population: Alzheimer's Treatment in Long Term Care
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This educational activity is designed for clinicians in long-term care (LTC) facilities involved in the care of residents with Alzheimer’s disease (AD) or other dementias, including (but not limited to) neurologists, geriatricians, nurse practitioners, and nurses.
Alzheimer's disease (AD) is the most common type of dementia and is estimated to affect 5 million individuals in the United States. Of all individuals over age 65 years, an estimated 6-8% have AD or another form of dementia and this rate exceeds 30% at age 85 years and older. Because the decline in cognitive abilities can be severe enough to interfere with daily life, clinicians who care for residents with AD can play a pivotal role in the diagnosis, treatment, and follow-up of these residents. As such, there is a significant need to provide long-term care clinicians with guidance on how to identify residents with AD, assess underlying mechanisms and disease severity, and how to establish and monitor an effective treatment plan.
PHYSICIANS AND OTHER HEALTHCARE PROFESSIONALS
Upon completion of this activity, participants should be able to
Upon completion of this activity, participants should be able to
Upon completion of this activity, participants should be able to
- Introduce nationally recognized quality measures to improve strategies for the screening, diagnosis, treatment and care of patients with AD and/or dementia within LTC facilities
- Analyze existing and emerging treatment paradigms in AD and consider implications for improved care within the LTC setting
- Differentiate patients with AD from those with other types of dementia or psychiatric disorders
Upon completion of this activity, participants should be able to
- Discuss assessment tools for the diagnosis of residents with AD in the LTC setting
- Analyze clinical guidelines for management of AD in the context of recent clinical trials and utilization of available therapeutic options
- Differentiate patients with AD from those with other types of dementia or psychiatric disorders
Cosponsored by Indiana University School of Medicine and The Academy for Continued Healthcare Learning
Supported by an educational grant from Pfizer Inc.
Stephen R. Connor, PhD
Senior Fellow, Worldwide Palliative Care Alliance
London, UK
International Palliative Care Consultant
Open Society Foundations
New York, NY
Altarum Institute
Washington, DC
Consultant Research Director, Capital Caring
Washington, DC
Senior Fellow, Worldwide Palliative Care Alliance
London, UK
International Palliative Care Consultant
Open Society Foundations
New York, NY
Altarum Institute
Washington, DC
Consultant Research Director, Capital Caring
Washington, DC
Indiana University School of Medicine requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. Conflict resolution must occur prior to the CME/CE activity. Indiana University School of Medicine also requires participating faculty to disclose when unapproved/unlabeled uses of a product are discussed in a CME/CE activity. This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. Indiana University School of Medicine requires the speaker to disclose that a product is not labeled for the use under discussion. The provider’s documentation of common practices that make the disclosure requirement known to faculty demonstrates compliance with ACCME guidelines.
The planning committee and faculty members have provided the following disclosure information.
Martin R. Farlow, MD (Course Director) Type of financial relationships:
Consultant: Accera, Inc.; Alltech; Astellas Pharma US, Inc.; Avanir Pharmaceuticals, Inc.; Bayer AG; Bristol-Myers Squibb; Eisai Co., Ltd.; Eli Lilly and Company; GE; Helicon Therapeutics, Inc.; MedAvante, Inc.; Medivation, Inc.; Merck & Co., Inc.; Novartis AG; Pfizer Inc; Prana Biotechnology Limited; QR Pharma, Inc; Roche; sanofi-aventis U.S. LLC.; Schering-Plough Corporation; Shire; Toyama Pharmaceutical Association; UCB, Inc
Speakers Bureau: Eisai Co., Ltd.; Forest Laboratories, Inc.; Novartis AG; Pfizer Inc
Grant/Research Support: Eisai Co., Ltd.; Eli Lilly and Company; Genentech, Inc. Novartis AG; Roche; sanofi-aventis U.S. LLC.
The following planning committee and faculty members have no relevant financial relationships with commercial interests, and will not discuss off-label use:
Faculty: Stephen R. Connor, PhD; Planning Committee: Mickey Vogel, MSN, RN and Tarra Barot, PhD
All conflicts of interest have been resolved through independent peer-review of the content to be presented.
The planning committee and faculty members have provided the following disclosure information.
Martin R. Farlow, MD (Course Director) Type of financial relationships:
Consultant: Accera, Inc.; Alltech; Astellas Pharma US, Inc.; Avanir Pharmaceuticals, Inc.; Bayer AG; Bristol-Myers Squibb; Eisai Co., Ltd.; Eli Lilly and Company; GE; Helicon Therapeutics, Inc.; MedAvante, Inc.; Medivation, Inc.; Merck & Co., Inc.; Novartis AG; Pfizer Inc; Prana Biotechnology Limited; QR Pharma, Inc; Roche; sanofi-aventis U.S. LLC.; Schering-Plough Corporation; Shire; Toyama Pharmaceutical Association; UCB, Inc
Speakers Bureau: Eisai Co., Ltd.; Forest Laboratories, Inc.; Novartis AG; Pfizer Inc
Grant/Research Support: Eisai Co., Ltd.; Eli Lilly and Company; Genentech, Inc. Novartis AG; Roche; sanofi-aventis U.S. LLC.
The following planning committee and faculty members have no relevant financial relationships with commercial interests, and will not discuss off-label use:
Faculty: Stephen R. Connor, PhD; Planning Committee: Mickey Vogel, MSN, RN and Tarra Barot, PhD
All conflicts of interest have been resolved through independent peer-review of the content to be presented.
All Academy for Continued Healthcare Learning and Indiana University School of Medicine staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
It has been determined that this online activity can be completed in 75 minutes. To receive credit, participants must complete the pre assessment survey, review the learning objectives and faculty disclsoures, view the slides and audio, reflect on the content, and complete the post-assessment survey and evaluation. A minimum score of 75% must be achieved on the post-assessment to receive credit. A certificate of credit will be immediately available once these requirements are met. There is no fee to participate in the program or for the generation of the certificate.
Hardware and Software Requirements |
|
Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. |
Indiana University School of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
Nurse Credit Statement This continuing nursing education activity was approved by the Ohio Nurses Association (OBN-001-91), an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Approval valid through Date May 1, 2015. ONA #16060 Approved for 1.1 contact hours. |
Nurse Practitioner Credit Statement This program is approved for 1.0 contact hour of continuing education by the American Academy of Nurse Practitioners. Program ID 1302107 |